



## **BioLight’s New Investment in Belkin Laser Ltd., a medical device company which develops an innovative one-second Glaucoma laser treatment**

Tel Aviv (December 22, 2019) – BioLight is pleased to announce that today, it has signed a binding agreement for its investment in Belkin Laser Ltd. (the “**Agreement**” and “**Belkin Laser**”). According to the Agreement, BioLight shall invest approx. USD 1M in consideration for the issuance of Preferred B shares in Belkin Laser, out of an investment round (including loans’ conversions), of up to USD 5M with other investors

According to the Agreement, Belkin Laser has the right to extend said investment round, up to a maximum total investment amount of up to USD 10M (the “**Total Investment**”) and in such framework, the Company has the right to extend its investment by additional approx. USD 100K. Following completion of its investment in Belkin Laser, the Company shall hold approx. 6% of the issued and fully paid up share capital of Belkin Laser (5% on a fully diluted basis). Assuming Total Investment, the Company shall hold approx. 5% of the issued and fully paid up share capital of Belkin Laser (approx..4% on a fully diluted basis).

To the Company’s best knowledge, Belkin Laser develops an innovative one-second Glaucoma laser treatment whose purpose is to enable glaucoma patients to receive a short and effective laser treatment as an initial treatment for the disease, instead of eye drops, and to bring to patients a proven and well-known laser treatment method (SLT) that is currently demanding a high practitioner's expertise and is involved in the discomfort of the patient (the “**Product**”). To the Company’s best knowledge, Belkin Laser’s technology is based on a license agreement from the “Sheba” Hospital and the Tel Aviv University, and is based on a patent registered by Professor Michael Belkin, the medical director of Belkin Laser. To the Company’s best knowledge, Belkin Laser has successfully completed a clinical trial in Israel and began a major clinical trial in Europe (England and Italy) in to obtain CE approval.

The investment in Belkin Laser joins BioLight's recent investments in Tarsius Pharma Ltd. and Sanoculis Ltd., and is aligned with BioLight's business strategy objectives and plans, and is in-line with its Ophthalmic core activity.